Friday, July 10, 2026
🇺🇸 FDA

Drug profile · INN

placebo

placebo is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 20
Pipeline programs 1,558
News articles 0
Drug details — placebo
Class
—
Route
—
Patents
20
Programs
1558
Data quality
0.70
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

placebo is an FDA-listed pharmaceutical active ingredient.

Key facts

INN placebo

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Search pipeline
  1. 0600-PG-PSC-218 Phase 3 · Anaxis Pharma · Allergic rhinoconjunctivitis with or without controlled asth
  2. 060018-PG-PSC-217 Phase 3 · Anaxis Pharma · Allergic rhinoconjunctivitis with or without asthma due to c
  3. 100-006 Phase 3 · Cardiol Therapeutics · Recurrent Pericarditis
  4. 1001 Phase 3 · Biotest Farmaceutica Ltda · Non-severe community-acquired pneumonia (CAP) or moderate or
  5. 101380003SA Phase 3 · Santen Oy · Acquired Blepharoptosis
  6. 1245-0256 Phase 3 · Boehringer Ingelheim · Chronic kidney disease in paediatric patients
  7. 1305-0023 Phase 3 · Boehringer Ingelheim · Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
  8. 1305-0046 Phase 3 · Boehringer Ingelheim · Systemic Autoimmune Rheumatic Diseases associated Interstiti

Related patents

Browse patents

  1. US 12410153

    Compounds, compositions and methods

    Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12410137

    Fatty acid amide hydrolase modulators, compositions comprising the same and uses thereof

    Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12404313

    GDNF fusion polypeptides and methods of use thereof

    Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12390509

    Pharmaceutical composition comprising frataxin fusion protein and methods of use thereof

    Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12371414

    Methods of treating neurological disorders

    Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12364737

    Activin receptor type IIA variants and methods of use thereof

    Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12350313

    Activin receptor type IIa variants and methods of use thereof

    Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12351611

    Molecules for organelle-specific protein delivery

    Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12269856

    Hepcidin analogues and uses thereof

    Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12269858

    Activin receptor type IIB variants and methods of use thereof

    Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12247025

    Processes for preparation of soluble guanylate cyclase stimulators

    Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12234300

    Conjugated hepcidin mimetics

    Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12178811

    Methods of treating depressive disorders

    Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12178875

    Lymphatic system-directing lipid prodrugs

    Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12171759

    Methods and uses for treating anhedonia

    Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12091437

    Molecules for organelle-specific protein delivery

    Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12036198

    Dosage forms and therapeutic uses of L-4-chlorokynurenine

    Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11993580

    Methods of treating neurological disorders

    Expires Mon May 23 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. AU 2022263543

    Pharmaceutical compositions comprising sorbitan esters

    Expires Wed May 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11976100

    Methods for treating myelin associated diseases and mitochondria associated diseases

    Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is placebo?

placebo is an FDA-listed pharmaceutical active ingredient.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.